AZD-6280

AZD-6280 is an investigational small molecule drug developed as a selective modulator of the gamma-aminobutyric acid A (GABA-A) receptor, with higher efficacy at the α2 and α3 subtypes compared to the α1 and α5 subtypes. It acts as a positive allosteric modulator, enhancing GABAergic neurotransmission specifically through these receptor subtypes. The compound was primarily investigated for its potential anxiolytic effects in generalized anxiety disorder, aiming to provide anxiolysis with fewer sedative or cognitive side effects than traditional benzodiazepines. Clinical studies have shown that AZD-6280 produces dose-dependent central nervous system effects distinct from those of lorazepam, suggesting a more favorable side effect profile[1][2][4][5].